Lomustine Combined With Anlotinib as Interventional Therapy for Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Above Treatment
NCT07632209
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
46
Enrollment
OTHER
Sponsor class
Conditions
SCLC, Extensive Stage
Interventions
DRUG:
Lomustine
DRUG:
Anlotinib
Sponsor
Yayi He